Choosing and Managing Direct Oral Anticoagulants (DOACs)
|
|
- Eugenia Stanley
- 5 years ago
- Views:
Transcription
1 Choosing and Managing Direct Oral Anticoagulants (DOACs) Ana G. Antun, MD, MSc Assistant Professor, Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University 1
2 Outline Efficacy and safety of DOACs compared to VKA s. Candidates for DOACs High-risk population Drug-drug interaction Measure of DOACs activity Management of DOAC interruption Management of bleeding 2
3 Site of Action of DOACs Tsakiris DA, et al. Semin Hematol. 2014;51(2):
4 General Characteristics of DOACs Characteristics Dabigatran Rivaroxaban Apixaban Edoxaban Betrixaban Target IIa Xa Xa Xa Xa Pro-drug Yes No No No No Half Life (hrs.) Route Elimination % Bioavailability Urine ~ 80 Feces ~ 20 ph dependent 6-7% Urine ~ 66 Feces ~ 26 Food dependent 66% Urine ~ 25 Feces ~ 50 Food dependent 50% Urine ~ 35 Feces ~ 60 Food dependent 62% Urine ~ 13 Feces ~ 80 Dosing Twice/day Once/day Twice /day Once/day Once/day Liver CP3A4 No < 2% Yes 57% Minor 25% Minor 35% No < 1% 34% Impact P-glycoprotein Yes Yes Yes Yes Yes Schaefer JK, et al. Ann Hematol. 2016;95(3):
5 DOACs vs. VKA Efficacy: noninferior Major Bleeding: 40% relative reduction Intracraneal and fatal bleeding: 60% relative reduction CRNM: clinical relevant nonmajor (minor) bleeding: 25% lower relative risk Gastrointestinal bleeding: no significant difference 5
6 Efficacy: DOACs vs. Warfarin van Es N, et al. Blood. 2014;124(12):
7 Safety: DOACs vs. Warfarin van Es N, et al. Blood. 2014;124(12):
8 Advantages and Disadvantages of DOACs Compared with VKA Advantages Disadvantages No routine monitoring No reliable, readily available measurement assay Improved safety profile Rapid onset (No bridging) Short half-life (advantage for invasive procedures or active bleeding) Fixed dosing Convenience Potential more cost-effective Fewer drug, disease and diet interactions Burnett AE, et al. J Thromb Thrombolysis. 2016;41(1): Dose reduction or avoidance in renal impairment and moderate or severe hepatic impairment No specific antidote Short half-life (mandates strict adherence) Less flexibility in dosing Fewer studies and approved indications (contraindicated in mechanical valve replacement) Potentially higher drug acquisition costs for patients DOACs drug interaction do exist that may preclude use 8
9 DOACs: Patient Selection Criteria Criteria for DOAC use Patient preference for and willingness to take DOAC No contraindication to DOAC therapy Adequate organ function No significant drug-drug interaction No significant disease state interaction Highly likely to be adherent to DOAC and follow up plan Confirmed ability to obtain DOAC from financial, insurance coverage stand point Comments Offer all therapeutic options with their respective advantages and disadvantages Pregnancy, breast feeding, mechanical valve Monitor renal function, age, concomitant use of p-gp/cyp3a4 inhibition Antiplatelet agents or NSAIDs History of GI bleed or at risk: warfarin, Apixaban or Edoxaban Drug cost vs generic warfarin + monitoring Assistance programs available Burnett AE, et al. J Thromb Thrombolysis. 2016;41(1):
10 Practical Management of DOACs in VTE Patient adherence assessment when choosing anticoagulant therapy Taking medication Laboratory monitoring Health care responsibility How often does the patient miss or forget to take doses of meds? If warfarin patient misses doses, switching to a shorter ½ life may predispose to the risk of thrombosis Sub-therapeutic INR is reliable indicator of doses have been missed Without lab monitoring, there is no opportunity to improve adherence Is once or twice daily dosing preferred? If patient is adherent to other twice daily med then DOAC is appropriate If patient prefers once daily meds then rivaroxaban or edoxaban Is Laboratory access difficult? Transportation challenges, difficult venous access, inflexible work or school schedule for difficulty complying with INR Annual renal function and complete blood count Is the patient reliable to notify provider about changes to health? Periprocedure anticoagulation plans Addressing medication interaction Unreliable patients to report issues may be better suited for warfarin 10
11 Special Populations To Avoid Pregnancy: category C Apixaban: category B (fetal exposure expected based on animal studies) Age: Avoid Dabigatran in patients > 75 years Extreme Weight < 50Kg > 120 Kg or BMI > 35 Kg/m2 Renal and hepatic insufficiency 11
12 Renal Adjustment Dose Adjustment Dabigatran Rivaroxaban Apixaban Edoxaban Betrixaban CrCl < 30 ml/min AVOID AVOID No adjustment 50% dose reduction 50% dose reduction CrCl < 15 ml/min Single dose post HD AVOID AVOID 12
13 Drug to Drug Interaction P-Glycoprotein CYP3A4 Inhibitors Carvedilol Clarithromycin Cyclosporine Erythromycin Azoles Tacrolimus Tamoxifen Grapefruit juice Azoles Grapefruit juice Protease inhibitors Inducers Dexamethasone Rifampin Phenytoin Carbamazepine St. John s Wort Phenytoin 13
14 Hepatic Adjustment Dose Adjustment Dabigatran Rivaroxaban Apixaban Edoxaban Betrixaban P-gp inducer AVOID AVOID P-gp inhibitor AVOID if CrCl < 50 50% dose reduction 50% dose reduction CYP3A4 and P-gp inhibitor AVOID 50% dose reduction CYP3A4 and P-gp inducer AVOID AVOID Child-Pugh B AVOID Caution Caution AVOID Child-Pugh C AVOID AVOID AVOID AVOID 14
15 Special VTE Populations To Avoid Thrombophilia: Antiphospholipid syndrome (APS) Heparin induced thrombocytopenia (HIT) Cancer-associated thrombosis History of bleeding VTE despite therapeutic INR Need for thrombolysis Massive PE hemodynamically compromise Venous gangrene and threatened limb loss 15
16 Antiphospholipid Syndrome and VTE The Rivaroxaban in AntiPhospholipid Syndrome (RAPS) study: APLS with previous VTE on warfarin for 6 months Primary end point: endogenous thrombin potential: NOT reach noninferiority No recurrent thrombosis in 6 months. (Son M, et al. Thromb Res. 2015;135(5): ) The Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS) study ( (to be completed 12/2018) The Rivaroxaban in Antiphospholipid Syndrome Pilot Study. (completed 12/2016) 16
17 Heparin Induced Thrombocytopenia DOACs for treatment of HIT as a primary or secondary therapy (non- DOAC transitioned to DOAC) Primary Endpoint: thrombosis during acute HIT: Rivaroxaban: None of 10 Hamilton patients and 2.2% (1/46) literature review Apixaban: 0/12 Dabigatran: 0/11 No bleeding Warkentin ET, et al. Blood T. Warkentin Winship et al. Cancer Blood Institute June 2017 Emory University 17
18 Cancer-Associated VTE Known Concerns Need 20 % all VTE related to cancer Increase risk of recurrent VTE Higher risk of major bleeding Current guidelines: LMWH over VKA LMWH burdensome LMWH easier to manage on chemotx Indefinite anticoagulation DOACs: Simple oral regimen No monitoring attractive alternative DOACs no direct comparison with LMWH Drug to drug interaction with antineoplastic agents Gastrointestinal absorption of DOACs in vomiting or chemoinduced intestinal mucosal defect 1500 cancer patients provide guidance for those that LMWH is not an option. Favorable cancer prognosis Limited life expectancy excluded Absolute recurrent VTE rate 5.9% post 6 months treatment How to manage during active chemotherapy? HEAD TO HEAD COMPARISON WITH LMWH Outcome: recurrence and bleeding 18
19 Cancer-Associated VTE Name Description Completion CANVAS (NCT ) Rivaroxaban Prophylaxis in ambulatory cancer (NCT ) Rivaroxaban in the treatment of VTE in cancer PRIORITY (NCT ) DOACs vs LMWH+/- warfarin in VTE patients Phase III: Rivaroxaban vs. Placebo in ambulatory cancer patient on therapy Phase III: Rivaroxaban vs. LMWH (NCT ) Phase II: Safety and Efficacy of Dalteparin vs. Rivaroxaban in cancer associated VTE 9/2019 VTE recurrence 7/2018 (Emory) recurrence 3/2018 Enoxaparin Dalteparin Tinzaparin 5/2020 Bleeding upper GI, hepatobiliar pancreatic 19
20 Cancer-Associated VTE Name Description Completion AVERT (NCT ) CARAVAGGIO (NCT ) Apixaban or Dalteparin reducing VTE in cancer Apixaban vs. Placebo for the Prevention of VTE in cancer Phase III: Apixaban vs. Dalteparin for Treatment cancer associated VTE Phase III: Apixaban vs. Dalteparin (NCT ) 12/2019 Prevention 6/2019 recurrence 11/2018 Bleeding MYELAXAT Apixaban in prevention of VTE in MM treated with imids Completed For 6 months Cancer VTE (NCT ) Phase IV: Endoxaban vs. Dalteparin Completed (Emory) recurrence and bleeding 20
21 Switching to/from DOACs Switching from Dabigatran Rivaroxaban Apixaban Edoxaban WARFARIN INR < 2.0 INR < 3.0 INR < 2.0 INR < 2.5 LMWH UFH Switching from DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN Start within 0-2 hours of the time of next scheduled dose of LMWH Start immediately after stopping UFH To Warfarin Start warfarin and overlap with dabigatran CrCl 50 ml/min, overlap 3 days CrCl ml/min, overlap 2 days CrCl ml/min, overlap 1 day Start 4 hours after stop UFH Start warfarin and LMWH at the time of next scheduled DOAC dose and bridge until INR 2 For 60 mg dose, reduce to 30 mg and start warfarin For 30 mg dose, reduce dose to 15 mg and start warfarin Stop Edoxaban when INR 2 Nick van Es et al. Winship Blood 2014;124:1968 Cancer Institute Emory University 21
22 Potential Indication for DOACs Measurement Detection of clinically RELEVANT levels Urgent or emergent invasive procedure Detection of EXPECTED on-therapy levels Assessing adherence Detection of EXCESSIVE levels Hemorrhage Neuraxial anesthesia Breakthrough thrombosis Changes in renal function Major trauma Potential thrombolysis in acute VTE Hemorrhage Hepatic impairment Accidental or intended overdose Drug interactions Advanced age 22
23 Suggested laboratory measurements of DOACs Drug Clinically relevant drug levels Clinical objective Estimate drug levels on therapy Excessive drug level Dabigatran Anti-Xa inhibitors: Rivaroxaban Apixaban Edoxaban Betrixaban TT: normal levels likely excludes relevant drug levels Anti-Xa: normal likely excludes relevant drug levels Dilute TT, ECA, ECT Anti-Xa Assays should be calibrated for specific drugs based on anti-xa assay Dabigatran: based on dilute thrombin time Normal aptt, excludes excess drug Diluted TT, ECA, ECT can quantitate Anti-Xa and PT Normal PT likely excludes excess drug levels Anti-Xa suitable for quantitation 23
24 DOACs Eligibility Good Candidates VTE not requiring thrombolysis Adequate liver Function: Childs-Pugh A-B No significant drug interactions In cancer-associated VTE if refuse LMWH Caution GI bleed CKD Elderly Poor compliance CYP3A4 interaction Agents to use Apixaban-Edoxaban Apixaban-Betrixaban Anti-Xa Rivaroxaban-Edoxaban-Betrixaban Dabigatran 24
25 DOACs Eligibility Not Candidates VTE requiring thrombolysis or hemodynamic compromise End Stage Renal disease and dialysis Inadequate liver Function: C Antiphospholipid syndrome Cancer-associated VTE VTE despite therapeutic warfarin Bleeding 25
26 Invasive Procedures Cessation in hours (doses to held) ClCr ml/min Low Bleeding Risk Dabigatran High Bleeding Risk Apixaban/Rivaroxaban /Edoxaban Low Bleeding Risk High Bleeding Risk Resumption Low Bleeding Risk High Bleeding Risk > 80 ~ 24 (2) ~ 48 (4) ~ (1-2) ~ 48 (2-4) ~ 36 (3) ~ 72 (6) ~ 72 (6) ~ 96 (8) ~ (1-2) ~ (1-4) ~ 48 (2-4) ~ 48 (2-4) ~ 24 hours post-op ~ hours post-op Not indicated ~ (2-4) ~ 72 (3-6) Burnett AE, et al. J Thromb Thrombolysis. 2016;41(1):
27 DOACs-Related Bleeding Management Risk Stratification Mild Bleeding Moderate Bleeding Severe/life-threatening Local hemostatic measures: Consider anticoagulant withdrawal (balance thrombotic and bleeding risk) General measures: Hold anticoagulant Mechanic compression Monitor hemodynamic status Volume replacement Definite interventions Blood products: RBC transfusion Plasma Platelets: on antiplatelet agents General measures and Blood products Intensive care Hemodynamic support Consider o 4-factor PCC (50 IU/Kg) o Activated PCC (80 IU/Kg) Adjuvant Therapies Charcoal Hemodialysis for Dabigatran removal Desmopressin Antifibrinolytic 27
28 DOACs and Bleeding Management Time since last dose < 4 hours 4-36 hours > 36 hours, < 48 hours with renal failure Activated charcoal Reversed immediately No Assess activity Yes Targeted Reversal Agent Prolonged aptt: Dabigatran is present contributing to bleeding Prolonged PT: Anti-Xa present Available Not Available Active DOAC Uncontrolled bleeding No or low activity Continue resuscitation Idarucizumab for Dabigatran Adnexanet alfa for anti-xa (pending approval) Activated PCC (thrombosis) 28
29 Summary DOACs are a significant advance in VTE treatment Offer treatment options, convenience, similar efficacy with better safety than convention therapy DOACs are suitable treatment option for a broad spectrum of patient but caution should be taken in extreme ages and weights 29
30 Summary Whether can safely be used in high-risk populations (cancerrelated, APS, HIT) is not proven. Use should be limited in this population Several reversal strategies are under evaluation and specific antidotes are being developed, but most interventions need further evaluation. 30
31 31
10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI
10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose:
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationReversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding
Reversal of Direct Oral Anticoagulants Cameron D Griffiths, MD, FRCPC Clinical Assistant Professor Division of Hematology UBC Objectives Review efficacy and safety data for Direct Oral Anticoagulants (DOACs)
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationManaging Bleeding in the Patient on DOACs
Managing Bleeding in the Patient on DOACs Spring 2016 Jean M. Connors, MD Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine, HMS Conflicts
More informationROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS
ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS Chee Yen Lin Consultant Haematologist NCIS Haematology National University Hospital Singapore Nomenclature direct oral anticoagulant
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationLa terapia del TEV nel paziente oncologico nell'era dei DOAC
XXVI CONGRESSO NAZIONALE FCSA Bologna, 5-7 Novembre 2015 Tromboembolismo venoso La terapia del TEV nel paziente oncologico nell'era dei DOAC ANNA FALANGA Immunoematologia e Medicina Trasfusionale e Centro
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationMy Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)?
My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)? November 24, 2018 Erica Peterson MD, FRCPC University of British Columbia Disclosures I participate in clinical research
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More informationAcute Care: Understanding Direct Oral Anticoagulants (DOACs)
Acute Care: Understanding Direct Oral Anticoagulants (DOACs) National Conference for Nurse Practitioners (NCNP) October 11, 2017 John Togami, PharmD, PhC Pharmacist Clinician - Outpatient Anticoagulation
More informationUpdate on the Management of Cancer Associated VTE
Update on the Management of Cancer Associated VTE Jean M. Connors, MD 2018 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Associate Professor
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationCancer Associated Thrombosis
Cancer Associated Thrombosis Can we use DOACs? D R. C Y N T H I A W U MD F R C P ( C ) D I V I S I O N O F H E M A T O L O G Y F A M I L Y P H Y S I C I A N S A N D C A N C E R C O N T R O L A P R I L
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationOptimal Management of Anticoagulation Therapy
Optimal Management of Anticoagulation Therapy An Educational Slide Set American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism Slide set authors: Eric Tseng MD MScCH, University
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationConsensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture
Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationPreventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE
Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE What Is Atrial Fibrillation? Atrial fibrillation also called AFib or AF is the most common abnormal heart rhythm, affecting an
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationOverview of the Direct Oral Anticoagulants
Original Article Nedaa Skeik, MD Abhishek Sethi Michele Shepherd, PharmD From: Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN Address for correspondence: Nedaa Skeik, MD Minneapolis
More informationWarfarin 2016: New State of the Art for an Old Drug
Warfarin 2016: New State of the Art for an Old Drug Dan Witt, PharmD Professor (Clinical) and Vice Chair, Department of Pharmacotherapy, Assistant Dean for Clinical Affairs, University of Utah College
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationVenous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017
Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationBMS Project ID: 432US /16
The Bristol-Myers Squibb/Pfizer Medical Alliance would like to inform you that the following sections of the prescribing information for ELIQUIS (apixaban) have been updated and the underlined text denotes
More informationThe Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs.
The Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs. Chris E. Holmes MD, PhD Assistant Director, Thrombosis and Hemostasis Program University of Vermont Dabigatran (Praxxada) Rivoraxaban
More informationManagement of Cancer Associated VTE
Management of Cancer Associated VTE Jean M. Connors, MD 2017 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine HMS
More informationA Brief History of the World of Anticoagulation
A Brief History of the World of Anticoagulation Allison Burnett, PharmD, CACP, PhC Clinical Assistant Professor- UNM College of Rx Antithrombosis Stewardship Pharmacist University of New Mexico Hospital
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationChallenges in Coagulation
Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from
More informationEdoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354) This document supports the
More informationAre the days of Warfarin numbered?
2 nd SAVTE Symposium Are the days of Warfarin numbered? YES Dr. Mohamed A. Abdelaal, MD, FRCPath, FRCPI Consultant Haematologist King Abdulaziz Medical City - Jeddah, Saudi Arabia 1 3 May 2012, Casablanca,
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More informationEdoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355) This document supports
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationHeparin-Induced Thrombocytopenia (HIT)
Heparin-Induced Thrombocytopenia (HIT) Joshua Ononuju, Pharm. D. Owensboro Medical Health Systems Objectives Overview Pathogenesis Risk factors Clinical Presentation and Diagnosis Treatment goals and options
More informationHemostasis and Thrombosis for Primary Care Providers: An Update. Andrew D. Leavitt, MD. May 21, Topic Outline. Direct Oral Anti-Coagulants DOACs
Hemostasis and Thrombosis for Primary Care Providers: An Update 43 nd Annual Advances in Internal Medicine Andrew D. Leavitt, MD May 21, 2015 Topic Outline Direct Oral Anti-Coagulants DOACs Update and
More informationADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL
Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic
More informationNovel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology
Novel Anticoagulant Drugs by: Dr. M. Kamandi Fellowship of hematology and Oncology A-Novel Oral Anticoagulants A drug that is: safe and effective has predictable pharmacology has few drug drug and drug
More informationDOACs in SPECIAL POPULATIONS
DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationUHL Guideline for Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults, with Direct Oral Anti-Coagulants
UHL Guideline for Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults, with Direct Oral Anti-Coagulants Trust Ref B11/2018 1. Introduction and Who Guideline applies to The introduction
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationAnticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationDOACs and CAT. 05 May 2017 NTW St Thomas Hospital
DOACs and CAT Alexander (Ander) Cohen Vascular Medicine / Haematology Guy s and St Thomas Hospitals, King s College, London 05 May 2017 NTW St Thomas Hospital Disclosures for Dr. Alexander (Ander) T. Cohen
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationA place for new oral anticoagulants in medicine: a fast evolving story
A place for new oral anticoagulants in medicine: a fast evolving story Prof Beverley Hunt MB ChB, FRCP, FRCPath, MD Chair of Thrombosis & Haemostasis, King s College, London Medical Director of Lifeblood:
More informationDiagnosis and Management of Heparin-Induced Thrombocytopenia (HIT)
ASH CLINICAL PRACTICE GUIDELINES VENOUS THROMBOEMBOLISM (VTE) POCKET GUIDE Diagnosis and Management of Heparin-Induced Thrombocytopenia (HIT) A POCKET GUIDE FOR THE CLINICIAN DECEMBER 08 Allyson M. Pishko,
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationNHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation
1 NHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation Atrial fibrillation (AF) affects about 1.2% of the population in the United Kingdom and accounts
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationCancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
More informationa. A pharmacist may order a baseline SCr per protocol
UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin
More informationDOACs in Non-AF Conditions: Judicious Use and Management. Kenneth A. Bauer, MD Professor of Medicine Harvard Medical School Boston, MA USA
DOACs in Non-AF Conditions: Judicious Use and Management Kenneth A. Bauer, MD Professor of Medicine Harvard Medical School Boston, MA USA Janssen rivaroxaban BMS apixaban Disclosures Daiichi Sankyo edoxaban
More informationContent 1. Relevance 2. Principles 3. Manangement
Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark
More informationIndividualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information